| Literature DB >> 29736421 |
Enrique Gomez-Figueroa1, Sofia Garcia-Trejo1, Raul Anwar Garcia-Santos1, Gerardo Quiñones-Pesqueira1, Juan Manuel Calleja-Castillo1.
Abstract
INTRODUCTION: From its initial report on two female patients in 1979 by J.O. Susac, Susac syndrome (SuS) or SICRET (small infarctions of cochlear, retinal and encephalic tissue) has persisted as an elusive entity. To date the available evidence for its treatment is based on case reports and case series. The largest systematic review described only 304 reported cases since the 1970s. Here we presented the first reported case to our knowledge in Mexican population and the unusual presentation in a pregnant patient. CASEEntities:
Keywords: Corpus callosum; Demyelinating disease; Neuroinflammation; Susac syndrome; Vasculitis
Year: 2017 PMID: 29736421 PMCID: PMC5933996 DOI: 10.1016/j.ensci.2017.12.004
Source DB: PubMed Journal: eNeurologicalSci ISSN: 2405-6502
Fig. 1MRI FLAIR sequence. Part 1 and 2 Pretreatment images shows hyperintense lesions with predominantly pericallosal involvement in the subependymal striatons and the snowball lesions. Part 3 and 4 shows IgIV post treatment changes with almost complete disappearance of the previous lesions.
Comparison of data of the different reported cases of Susac syndrome with onset in pregnancy.
| Cases | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
|---|---|---|---|---|---|---|---|---|
| Published by | Gordon19918 | McFayden19879 | Hua201410 | Ionnides201311 | Engelholm201312 | Antulov201413 | Feresiadou201414 | Our case |
| Origin | US | Canada | US | Australia | Germany | Croatia | Sweden | Mexico |
| Age | 28 | 31 | 25 | 28 | 32 | 21 | 35 | 34 |
| Gestational age at onset (weeks) | 28 | No specified | 14 | 13 | 32 | 35 | 37 | 15 |
| Previous medical history | None | None | None | Epilepsy from a perinatal ischaemic event | None | None | Apparent similar clinical picture at 12 yo, treated with steroids | None |
| System of onset | Eye | Eye | Auditory | Neurologic | Neurologic | Neurologic | Auditory | Auditory |
| Neurologic symptoms | Unilateral weakness, dysarthria and apathy | Ataxia and dysarthria | Amnestic syndrome, Gait disorder, Bilateral severe weakness | Bilateral severe weakness and dysarthria | Encephalopathic syndrome and Unilateral weakness | Bilateral severe weakness and progressive cognitive affection | None | Cognitive affection (frontal medial syndrome) and bilateral weakness |
| Ophthalmologic symptoms | Visual field deficit | Visual field deficit | Loss of visual acuity | Loss of visual acuity | Visual field deficit | None | Loss of visual acuity and visual field deficit | Loss of visual acuity |
| Auditory symptoms | Bilateral neurosensorial hearing loss | Bilateral tinnitus and neurosensorial hearing loss | Tinnutus | Right neurosensorial hearing loss | Neurosensorial hearing loss | Left neurosensorial hearing loss | Tinnitus and left neurosensorial hearing loss | Tinnitus and bilateral neurosensorial hearing loss |
| Additional or atypical affection | None | None | Cervical cord involvement | None | Livedo racemosa | None | None | None |
| Time until fully triad (months) | 1 | 2 | 6 | 4 | 1.5 | Not completed | Not completed | 6 |
| MRI findings | ||||||||
| Deep grey matter | No | Not done | Yes | Yes | Yes | Yes | No | Yes |
| White matter | Callosal and periventricular | Not done | Callosal and periventricular lesions | Callosal | Callosal and periventricular lesions | Callosal and periventricular lesions | No | Callosal |
| Posterior fossa involvement | No | Not done | Yes | No, but also reported meningeal enhancement | Yes | Yes | No | No |
| Gadolinium enhancement | No reported | Not done | Yes | No reported | Yes | No reported | No | Yes |
| CSF findings | ||||||||
| Proteins mg/dl | No reported | 252 | 95 | 2000 | 1800 | 1009 | No performed | 77 |
| Cells (Mono) | No reported | 0 | 6 | 9 | No reported | No reported | No performed | 0 |
| Treatment | ||||||||
| Initial treatment | Heparin | None | IVMP × 5 | IVMP × 3 | IVMP × 5 | IGIV × 5 | IVMP × 5 | IVMP × 5 |
| Response | Partial | Partial | No response | Partial | Complete response | Partial | No response | |
| 2nd line treatment | None | None | Oral prednisone | PLEX and IVIg | Oral prednisone | None | None | IgIV |
| Chronic treatment | Warfarin | Oral prednisone | MMF | MMF | MMF + MTX | AZA | Oral prednisone | CCF |
| Response | Almost complete recovery | Partial remission | Partial remission | No response | Almost complete recovery | Almost complete recovery | Almost complete recovery | Partial remission |
| Prognosis | ||||||||
| Follow up (years) | 0.2 | 4 | 1.5 | 3.5 | 1 | 0.2 | 3 | 0.5 |
| Sequels | Visual deficit | Mild hearing loss | Cognitive deficit with visuospatial and word recall | No specified | Mild cognitive deficit | Subtle weakness | Mild left hearing loss | Cognitive deficit |
| Course of disease | Monocyclic | Monocyclic | Chronic continuous | Probably Monocyclic | Probably Monocyclic | Monocyclic | Probably Monocyclic | |
| Final pregnancy state | Healthy product | Healthy product | Healthy product | Therapeutic abortion at 15 weeks GA | Healthy product | Healthy product | Healthy product | Therapeutic abortion at 17 weeks GA |